阿尔茨海默病异常黑胆质病证结合大鼠模型血清代谢组学研究

doi:10.3981/j.issn.1000-7857.2014.h2.004

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (2287 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract: To investigate the metabolic characteristics of alzheimer's disease (AD) rat model with abnormal savda syndrome, an abnormal savda rat model with multiple factors is established according to the theory of Uighur traditional medicine, and Aβ_1-40 ventricle injection is carried out to establish the alzheimer's disease rat model with abnormal savda syndrome. Then, serum samples from all group rats are analyzed by nuclear magnetic resonance (¹H-NMR) spectroscopy (600 MHz), and their spectral profiles are projected by orthogonal projections to latent structures (OPLS-DA) for multivariate statistics. The OPLS-DA analysis shows that compared to the normal group, the pure AD group serum has higher levels of lactic acid, glycoproteins, acetone, VLDL, formic acid and unsaturated lipids, yet a lower level of malonic acid. The abnormal savda syndrome group serum has higher levels of glycoproteins and β-glucose, but lower levels of valine, tyrosine, phenylalanin, and 1-methyl-histidine. The anormal savda syndrome AD group serum has a higher level of unsaturated lipids, but lower levels of glycine, phenylalanine, 1-methyl-histidine, methionine, malonic acid, α-glucose and β-glucose (P<0.05). Compared to the pure AD group, the abnormal savda syndrome group serum has lower levels of leucine, valine, alanine, tyrosine, α-glucose, β-glucose, carnitine, citric acid and unsaturated lipids. The abnormal savda syndrome AD group serum has lower levels of alanine and acetone, but higher levels of β-glucose and creatine (P<0.05). Compared with the abnormal savda syndrome group, the abnormal Savda syndrome AD group serum has higher levels of α-glucose, β-glucose, carnitine and citric acid (P<0.05). It is concluded that the abnormal savda syndrome has certain relevance to the development of alzheimer's disease; compared with the abnormal savda syndrome group and pure AD group, the alerted metabolits and metabolic pathway related with disordered glucose metabolism and energy dysmetabolism have variations during the pathological changing process of disease, and the variation of metabolism in the body of abnormal savda syndrome AD rat is more complex.

Key words： abnormal savda syndrome alzheimer's disease metabonomics NMR Uyghur medicine

Received: 26 May 2014

ZTFLH:

R291.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.kjdb.org/EN/10.3981/j.issn.1000-7857.2014.h2.004 OR http://www.kjdb.org/EN/Y2014/V32/I28/29/39

[1] 苏怡汀, 李乐华. 阿尔茨海默病的神经生物学发病机制及相关治疗研究进展[J]. 医学临床研究, 2011, 28(5): 947-951.Su Yiting, Li Lehua. The neurobiology of pathogenesis of alzheimer'sdisease and related treatment progress[J]. Journal of Clinical Research,2011, 28(5): 947-951.
[2] Roger N, Rosenberg M D. Translational research on the way to effectivetherapy for Alzheimer disease[J]. Archives of General Psychiatry, 2005,62(11): 1186-1192.
[3] Mayeux R. Epidemiology of neurodegeneration[J]. Annual Review ofNeuroscience, 2003, 26(6): 81-104.
[4] 艾来提·米吉提, 阿地里江·阿不力米提, 尼加提·热合木, 等. 维医异常黑胆质成熟剂对异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴形态学的影响[J]. 国际病理科学与临床杂志, 2008, 28(1): 6-9.Hairat Mijit, Adiljan Abilmit, Nijat Rahman, et al. Effect of abnormalSavda munziq on morphological structure of hypothalamus-pituitaryadrenalaxis cells in abnormal Savda syndrome animal model[J].International Journal of Pathology and Clinical Medicine, 2008, 28(1):6-9.
[5] 哈木拉提, 阿不都热依木, 阿不都艾尼. 维吾尔医成熟剂和清除剂抗活性氧的作用研究[J]. 中国民族医药杂志, 2000(3): 30-32.Halmuat, Abuduriyimu, Abuduaini. Study on antioxidation of mature andcleaning prescriptions in Uigher medicine[J]. China National MedicalJournal, 2000(3): 30-32.
[6] 阿布都艾尼, 阿不都热依木, 哈木拉提. 异常黑胆质成熟剂和清除剂对OH黑引发的DNA损伤的保护作用[J]. 中药药理与临床, 2000, 16(3): 33-36.Abuduaini, Abudureyimu, Halmurat. The protect effect of on Abnormalsavda munziq and mushily on OH caused DNA damage[J].Pharmacology and Clinics of Chinese Materia Medica, 2000, 16(3): 33-36.
[7] 哈木拉提·吾甫尔, 阿依努尔·买提斯迪克, 努尔买买提·艾买提, 等.异常黑胆质证载体动物模型的建立及其自然恢复反证[J]. 新疆医科大学学报, 2006, 29(10): 910-914．Upur Halmurat, Matsidik Aynur, Amat Nurmammat, et al. Theestablishment and evaluation of abnormal Savda syndrome animal model[J]. Journal of Xinjiang Medical University, 2006, 29(10): 910-914．
[8] 阿不都卡德尔·库尔班, 斯坎达尔·白克力, 哈木拉提·吾甫尔, 等. 异常黑胆质证载体Ⅱ型糖尿病SD大鼠模型的及其生物学基础研究[J].新疆医科大学学报, 2011, 11(12): 914-916．Kurban Abdukadir, Bakri Iskandar, Upur Halmurat, et al.Establishment of abnormal Savda syndrome carrying type 2 diabetes ratmodel and study on its Biological basis[J]. Journal of Xinjiang MedicalUniversity, 2011, 11(12): 914-916．
[9] 阿依努尔·买提斯迪克, 尼加提·热合曼, 哈木拉提·吾甫尔, 等. 异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴组织形态学观察[J]. 新疆医科大学学报, 2006, 29(10): 914-916．Matsidik Aynur, Rahman Nijat, Upur Halmurat, et al. Observation ofhypothalamus-pituitary-adrenal axis in animal model of abnormalSavda syndrome[J]. Journal of Xinjiang Medical University, 2006, 29(10): 914-916．
[10] 阿地力江·阿不力米提, 胡汉华, 艾来提·米吉提, 等. 异常黑胆质成熟剂对异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴细胞超微结构的影响[J]. 国际病理科学与临床杂志, 2007, 27(3): 185-191．Adlijan Abilimit, Hu Hanhua, Mijit Hairat, et al. Effect of abnormal Savda munziq on the cell ultra-structure of hypothalamus-pituitaryadrenalaxis cells in abnormal Savda syndrome animal model[J].International Journal of Pathology and Clinical Medicine, 2007, 27(3):185-191．
[11] 玉苏甫·吐尔逊, 斯坎达尔·白克力, 哈木拉提·吾甫尔. 异常黑胆质性肝癌病证模型肝硬化期的肝脏形态学研究[J]. 科技导报, 2010, 28(24): 82-89．Tursun Yusup, Iskandar Bakri, Halmurat Upur. Morphological studyon hepatic tissue in hepatocirrhosis phase of hepatocarcinoma darryingabnormal Savda model[J]. Science & Technology Review, 2010, 28(24): 82-89．
[12] Paxinos G, Watson C. The rat brain in stereotaxic coordinates[M]. NewYork: American Academic Press, 1986: 2.
[13] Morris R G M. Spatial localization does not require the presence oflocal cues[J]. Learning Motivation, 1981, 12(2): 239-260.
[14] 方福德. 现代医学实验技巧全书[M]. 第1版. 北京: 北京医科大学和中国协和医科大学联合出版社, 1995: 420-425.Fang Fude. Modern medical experimental skills[M] 1st ed. Beijing:Medical University and China Union Medical University AssociatedPress, 1995: 420-425.
[15] 牛丰南, 孙宗正, 徐运. 阿尔茨海默病早期诊断的分子靶标研究进展[J]. 国际神病学神经外科学杂志, 2009, 36(1): 86-90.Niu Fengnan, Sun Zongzheng, Xu Yun. Research progress ofmolecular targets in early diagnosis of Alzheimer's disease[J].International Journal of Psychiatry Department of Neurosurgery, 2009,36(1): 86-90.
[16] 姚洁, 王培昌. 脑脊液生物学标志物的检测在阿尔茨海默病诊断中的应用[J]. 中国老年学杂志, 2007, 27(16): 1631-1635.Yao Jie, Wang Peichang. Application of CSF biomarker's concentrationfor the diagnosis of Alzheimer's disease[J]. Chinese Journal ofGerontology, 2007, 27(16): 1631-1635.
[17] 许国旺, 路鑫, 杨胜利. 代谢组学研究进展[J]. 中国医学科学院学报,2007, 29(6): 701-711.Xu Guowang, Lu Xin, Yang Shengli. Recent advances inmetabonomics[J]. Journal of Chinese Academy of Medical Sciences,2007, 29(6): 701-711.
[18] 艾斯克尔·吐拉洪, 哈木拉提·吾甫尔, 巴吐尔·买买提明, 等. 基于NMR的维吾尔医异常黑胆质型肿瘤患者血浆代谢组学分析[J]. 科技导报, 2009, 27(13): 27-31.Turahun Askar, Upur Halmurat, Mamtimin Batur, et al. Metabonomicstudies on abnormal Savda syndrome patients with neoplasm usingNMR spectroscopy[J]. Science & Technology Review, 2009, 27(13):27-31.